Site Name: _____ Participant Number: | | | | | | |

Eligibility Confirmation Checklist

Please review eligibility criteria set out below and ensure participant meets all criteria with the exception of 'Provision of informed consent'. If participant meets eligibility criteria please follow consent process as defined in protocol.

PROVISIONAL ELIGIBILITY		**Yes**	**No**
Is the participant provisionally eligible to proceed with the informed consent process.			
Provisional Eligibility assessed by Signature	*Print Name*	*Date (DD/MM/YYYY)*	*Time (HH MM)*

Please complete the following sections for each participant when confirming eligibility after consent.

	Inclusion Criteria **(All must be marked YES to proceed)**	**Yes**	**No**
a	Provision of informed consent		
b	Aged 16 years or older		
c	Admitted to intensive care unit or high dependency unit (ICU)		
d	Receiving respiratory support via invasive mechanical ventilation or non-invasive ventilatory support (non-invasive ventilatory support includes mask or helmet) or high flow nasal cannula (HFNC) >30L/min		
e	Within 72 hours of diagnosis of ARDS with moderate to severe hypoxaemia defined as : i) a known acute clinical insult or new or worsening respiratory dysfunction (Note: this includes new deterioration at any time-point during the ICU stay), and ii) opacities on chest imaging not fully explained by effusions, lobar/lung collapse/atelectasis, or nodules, and iii) respiratory failure not fully explained by cardiac failure or fluid overload, and iv) assessment of hypoxaemia done with either PaO_2/FiO_2 ratio <26.7 kPa from arterial blood gases, or SpO_2/FiO_2 <235 with SaO_2<97%		

Protocol section 4.2.1 'Additional Notes on Inclusion Criteria':

- Patients who change from mild hypoxaemia to moderate or severe hypoxaemia are eligible
- Patients with unilateral opacities are eligible (see protocol section 4.2.1 for further details

Site Name: _____ Participant Number: | | | | | | |

	Exclusion Criteria **(All must be marked NO to proceed)**	Yes	No
a	ARDS due to microbiologically confirmed SARS-Co-V2 infection (COVID-19 ARDS)*		
b	Major upper gastrointestinal bleeding during current hospital admission, defined as requiring endoscopy and transfusion for two or more units of packed red blood cells. This exclusion criterion will exclude patients with contraindications to the glucocorticoids on the grounds of safety.		
c	High dose glucocorticoids are required for a separate proven clinical indication at the time of randomisation as withholding treatments that have been deemed clinically effective, would be unethical. **Note:** *Low dose glucocorticoid treatments for clinical indications (defined as maximum daily dose of 200mg hydrocortisone or equivalent other steroids) is not an exclusion criterion.**		
d	Known hypersensitivity to dexamethasone.		
e	Infections that are not being effectively treated as determined by the treating medical team. **Note:** *Once infections are considered as effectively treated by the treating medical team, they are eligible for the trial.*		
f	Planned intensive care treatment withdrawal within next 24 hours as determined by the treating medical team.		
g	Patients who are known to be pregnant*		
h	Previous enrolment in the GuARDS trial		

* For additional notes on this exclusion criteria please see Protocol section 4.3.1 'Explanatory Notes on Exclusion Criteria'

ELIGIBILITY CONFIRMATION		Yes	No
I confirm the participant is eligible to proceed to randomisation.			
Eligibility confirmed by Signature (Medic only)	*Print Name*	*Date (DD/MM/YYYY)*	